Linerixibat is a small molecule commercialized by GSK, with a leading Phase III program in Pruritus. According to Globaldata, it is involved in 15 clinical trials, of which 12 were completed, and 3 ...

With that in mind, GSK is partnering with developer Reef and investor UBS Asset Management to build a 1.4M SF, £900M life ...

The outlook for the pharmaceutical market in the UAE is highly promising, supported by the government’s strong commitment to ...

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

The partnership revolves around Muna Therapeutics’ technology platform, which employs a spatial multi-omics approach to ...

The plans are for powering the nearby GSK factory, but Historic Environment Scotland, National Air Traffic Services and ...

Muna will take the lead in identifying and validating new Alzheimer’s targets, while GSK will be responsible for the ...

Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in ...

In November 2024, the European Commission approved GSK's single-vial, fully liquid Menveo vaccine (MenACWY). "Muna-GSK ...

Multi-year effort leverages Muna's all-in-human MiND-MAP spatial multi-omics approach to identify and validate new drug targets and treatment pathways for ...

DualityBio entered into an exclusive $1 billion option agreement with GSK for DB-1324. Thermo Fisher Scientific completed its ...

The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...